Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Income: 2009-2024

Historic Operating Income for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $41.9 million.

  • Tg Therapeutics' Operating Income rose 136.17% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 20452.28%. This contributed to the annual value of $41.9 million for FY2024, which is 103.21% up from last year.
  • Per Tg Therapeutics' latest filing, its Operating Income stood at $41.9 million for FY2024, which was up 103.21% from $20.6 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Operating Income registered a high of $41.9 million during FY2024, and its lowest value of -$344.8 million during FY2021.
  • Moreover, its 3-year median value for Operating Income was $20.6 million (2023), whereas its average is -$51.9 million.
  • Its Operating Income has fluctuated over the past 5 years, first slumped by 61.84% in 2020, then spiked by 109.45% in 2023.
  • Over the past 5 years, Tg Therapeutics' Operating Income (Yearly) stood at -$273.6 million in 2020, then declined by 26.02% to -$344.8 million in 2021, then skyrocketed by 36.68% to -$218.3 million in 2022, then soared by 109.45% to $20.6 million in 2023, then skyrocketed by 103.21% to $41.9 million in 2024.